In the phase I trial NCT03260491, patients with EGFR-mutant NSCLC progressing to an anti-EGFR TKI who received HER3-DXd showed responses across a wide range of HER3 membrane expression levels, even if a trend toward increased responses was seen for higher H-scores [73]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.